Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

er 30, 2013, total (i.e., cash and non-cash) operating expenses, excluding the litigation expense, increased by $3.1 million compared to the same period in 2012. The increase was primarily due to the non-cash rent and stock-based compensation expenses of $3.2 million in 3Q 2013 compared to $576,000 in 3Q 2012. The remaining increases were related to conducting the company's Phase 1 clinical program evaluating OMS824, advancing our MASP-2 program, preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for OMS302, planning for the commercial launch of OMS302 in the second half of 2014, and non-recurring legal expenses incurred in connection with the CCIC matter. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of the company's OMS302 Phase 3 clinical program in January 2013 and the completion of the company's first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended September 30, 2013 was $196,000 compared to $1.4 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended September 30, 2013, Omeros reported a net loss of $13.9 million, or $0.46 per share, inclusive of the above-referenced $3.2 million of non-cash charges equaling $0.11 per share, compared to a net loss of $13.3 million, or $0.51 per share, inclusive of the above-referenced $576,000 of non-cash charges equaling $0.02 per share, for the same period in 2012.

At September 30, 2013, Omeros had cash, cash equivalents and short-term investments of $9.0 million. On October 24, 2013, subseque
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
(Date:3/26/2015)... 26, 2015 Ale Gicqueau, Founder and ... of Clinical Affairs at Align Technology, on “ Conducting ... upcoming ACRP 2015 Global Conference and Exhibition on April ... , During the poster presentation, Ale Gicqueau and ... running a Postmarket Registry, the requirements and resources to ...
(Date:3/25/2015)... MN (PRWEB) March 26, 2015 Agnition ... upcoming episode of American Farmer, airing for the first ... The segment of American Farmer will explore the extremely ... provides crop producers with a patented Microbial Catalyst™ technology ... and greater yields. The segment will air again on ...
(Date:3/25/2015)... 25, 2015 The surging prevalence ... have fuelled social media growth, with over 50% ... in social networking. Insurance companies are making use ... clients and promote a diversity of their services ... increasingly exploiting social networking services as part of ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3
... wholly owned subsidiary of British company Innovative Carbon Limited today ... 10th April to 13th. , Graphene, a sheet of carbon ... wonder material. First isolated at Manchester University in 2004, ... race has been on to produce it commercially. To ...
... April 6, 2012 Arteriocyte, a leading biotechnology ... Massachusetts announced today approval from the Food and ... clinical trial using its Magellan MAR01™ technology in ... Device Exemption (IDE 15013) allows Arteriocyte and its ...
... 2012  GenVec, Inc. (NASDAQ:   GNVC) announced publication ... vectors circumvent neutralizing antibodies in order to generate ... published online in PloS ONE, and can be ... "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing ...
Cached Biology Technology:UK company to demonstrate their commercially effective graphene production process 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 3GenVec Announces Research on Improved Vaccine Vectors 2GenVec Announces Research on Improved Vaccine Vectors 3
(Date:3/10/2015)... , March 10, 2015 Transforming ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured by ... past two years. Specifically, "Personalized Medicine in ... scientific papers published in 2013 and 2014 from Springer ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biometrics Market Forecast and Opportunities, 2020" ... market for biometric authentication systems is projected to ... 2020 The driving forces for this ... government projects and constant development in technology. In ...
(Date:3/2/2015)... Lithuania , March 2, 2015   Neurotechnology ... technologies, today introduced the SentiGaze Software Development Kit ... to create applications that use off-the-shelf webcams to track ... user gazes at a monitor. Heatmaps can be used ... the effectiveness of online advertising. The SDK can also ...
Breaking Biology News(10 mins):"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... In evaluating the bioactive compounds of Illinois blueberry ... compounds that inhibit enzymes responsible for carbohydrate absorption and ... help people with diabetes decrease their blood sugar. ... that would optimize the inhibition of the alpha-amylase and ...
... Philadelphia, PA, August 20, 2012 The more that ... The same can be said about the genetics and ... disease, mutation of a single gene predictably produces a ... to Mendelian disorders, understanding bipolar disorder has been extremely ...
... Hillel was named the 2012 recipient of the World ... have advanced human development by improving the quality, quantity, ... Hillela more than 50-year member of the Soil Science ... the 2012 International Annual Meetings of the American Society ...
Cached Biology News:Drink made from berry wine may provide tasty drug for diabetes 2Making sense out of the biological matrix of bipolar disorder 2World Food Prize winner among speakers at agronomy, crop and soil science societies meetings 2World Food Prize winner among speakers at agronomy, crop and soil science societies meetings 3